Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

G. Fürstenberger, R. Von Moos, Rudolf Lucas, B. Thürlimann, H. J. Senn, J. Hamacher, E. M. Boneberg

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

Original languageEnglish (US)
Pages (from-to)524-531
Number of pages8
JournalBritish Journal of Cancer
Volume94
Issue number4
DOIs
StatePublished - Feb 27 2006
Externally publishedYes

Fingerprint

Angiogenesis Inducing Agents
Endothelial Cells
Breast Neoplasms
Drug Therapy
Serum
Angiopoietin-2
Stem Cells
Erythropoietin
Vascular Endothelial Growth Factor A
Neoplasms
Endostatins
Vascular Endothelial Growth Factor Receptor-2
Breast Diseases
Anthracyclines
Secondary Prevention
Combination Drug Therapy
Population
Flow Cytometry
Cell Count
Bone Marrow

Keywords

  • Angiogenesis
  • Angiogenic factors
  • Breast cancer
  • Chemotherapy
  • Circulating endothelial cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. / Fürstenberger, G.; Von Moos, R.; Lucas, Rudolf; Thürlimann, B.; Senn, H. J.; Hamacher, J.; Boneberg, E. M.

In: British Journal of Cancer, Vol. 94, No. 4, 27.02.2006, p. 524-531.

Research output: Contribution to journalArticle

Fürstenberger, G, Von Moos, R, Lucas, R, Thürlimann, B, Senn, HJ, Hamacher, J & Boneberg, EM 2006, 'Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer', British Journal of Cancer, vol. 94, no. 4, pp. 524-531. https://doi.org/10.1038/sj.bjc.6602952
Fürstenberger, G. ; Von Moos, R. ; Lucas, Rudolf ; Thürlimann, B. ; Senn, H. J. ; Hamacher, J. ; Boneberg, E. M. / Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. In: British Journal of Cancer. 2006 ; Vol. 94, No. 4. pp. 524-531.
@article{88d947c4c7bf4226aa78ed0706200ee4,
title = "Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer",
abstract = "Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.",
keywords = "Angiogenesis, Angiogenic factors, Breast cancer, Chemotherapy, Circulating endothelial cells",
author = "G. F{\"u}rstenberger and {Von Moos}, R. and Rudolf Lucas and B. Th{\"u}rlimann and Senn, {H. J.} and J. Hamacher and Boneberg, {E. M.}",
year = "2006",
month = "2",
day = "27",
doi = "10.1038/sj.bjc.6602952",
language = "English (US)",
volume = "94",
pages = "524--531",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

AU - Fürstenberger, G.

AU - Von Moos, R.

AU - Lucas, Rudolf

AU - Thürlimann, B.

AU - Senn, H. J.

AU - Hamacher, J.

AU - Boneberg, E. M.

PY - 2006/2/27

Y1 - 2006/2/27

N2 - Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

AB - Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-I as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CDI33+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

KW - Angiogenesis

KW - Angiogenic factors

KW - Breast cancer

KW - Chemotherapy

KW - Circulating endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=33344459620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344459620&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602952

DO - 10.1038/sj.bjc.6602952

M3 - Article

VL - 94

SP - 524

EP - 531

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -